This Phase 1, double-blind, randomized, placebo-controlled study will characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending nighttime doses of JZP441 in sleep-deprived healthy participants.
1 Primary · 3 Secondary · Reporting Duration: Predose and the following postdose hours: 0.25,0.5,0.75,1,1.5,1.75,2.75,3 and 3.5,3.75,4.75,5 and 5.5,5.75, 6.25 and 6.5,6.75,7 and 7.5,7.75,8.75,9.75,10.75,11.75,12.75,13.75,16,18,24,36
Experimental Treatment
Non-Treatment Group
132 Total Participants · 2 Treatment Groups
Primary Treatment: JZP441 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 50 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 33.3% |
Connecticut | 33.3% |
New Jersey | 33.3% |
Clinical Site 1 | 66.7% |
Clinical Site 2 | 33.3% |
Met criteria | 100.0% |
0 | 100.0% |
100.0% | |